Exicure, Inc. is a clinical-stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs based on their proprietary spherical nucleic acid (SNA) technology. Their pipeline is focused on targeting diseases such as cancer, inflammatory disorders, and genetic diseases. Exicure's lead product candidate, AST-008, is currently in clinical trials for the treatment of advanced solid tumors.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

9 Patents

#384 in Chicago, IL

#1,549 in Illinois

#32,588 in US

Chicago, IL, United States of America

Exicure, Inc.

Forward Citations = 74

14 inventors:

Sergei M Gryaznov (8 out of 84 patents)

Christopher C Mader (8 out of 10 patents)

Aleksandar Filip Radovic-Moreno (6 out of 23 patents)

4. Chad A Mirkin (3 out of 168 patents)

5. SonBinh T Nguyen (3 out of 30 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Exicure, Inc.. Retrieved from https://idiyas.com/company/exicure

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]